---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000003"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:02:40.568459+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibrx secures $150M loan facility from Oxford Finance; $100M funded upfront

## Summary
- Loan and Security Agreement with Oxford Finance for up to $150M term loan; $100M funded on Jan 13, 2025.
- Remaining $50M available at Inhibrx's request and Lenders' sole discretion.
- Interest-only payments through Feb 2028; maturity Jan 1, 2030; rate = 1M SOFR + 5.61% (floor 4.34%).
- Issued warrants for 140,741 shares at $14.21/exercise price, representing 2% of initial $100M tranche.
- Proceeds provide strategic flexibility ahead of expected data readouts for INBRX-109 and INBRX-106 programs.

## SEC filing metadata
- accession: 0002007919-25-000003
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/0002007919-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/inhibrx-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000003
- JSON: https://secwatch.observer/filing/0002007919-25-000003.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.